Sitemap
En
Press Release
Current Location: Home > Press Release > Investment News & Information

Bloomage Biotech Builds China’s Largest Pilotscale Experiment Platform in TEDA

12-21-2022


Recently, Bloomage Biotechnology (Tianjin) Co., Ltd. has officially started the construction of a pilotscale experiment plant for pharmaceutical grade raw materials in Nangang Industrial Zone of TEDA. Expected to be completed and put into operation in 2024, the project covers a construction area of about 28,000 square meters with a total investment of 630 million yuan. After the plant is up and running, it will be able to conduct pilotscale experiment and R&D of six categories of substances, including pharmaceutical-grade peptides, proteins, polysaccharides, amino acids, nucleotides and plant bioactives. By then, the total area of the Bloomage Biotech Tianjin Plant will reach 40,000 square meters, making it the largest pilotscale experiment plant in China.


Bloomage Biotech is currently the world’s largest supplier of hyaluronic acid raw materials, and its microbial fermentation technology of hyaluronic acid production is in the international leading position. The company incorporated a wholly-owned subsidiary, Bloomage Biotechnology (Tianjin) Co., Ltd. in TEDA in 2018. The Tianjin subsidiary takes the three major technology of fermentation, crosslinking and technological TCM(Traditional Chinese Medicine) as the core, and produce food-grade, cosmetic-grade and pharmaceutical-grade hyaluronic acid raw materials and other products in phases, and can carry out the R&D incubation of related raw materials.



TOP
Website Identification Code: 1201160062

Are you sure you want to leave this page?